The obesity drug market and the Fed’s perspective on inflation
Nov 11th, 2023 - This week AstraZeneca has entered into the obesity drug market by acquiring ECC5004, an experimental weight-loss pill, sparking competition with Eli Lilly and Novo Nordisk. Although AstraZeneca's move initially impacted Eli Lilly's stock negatively, the company maintains a first- mover advantage with a more sophisticated obesity pill in development. The GLP-1 drug market, known for blood sugar control and weight loss, is lucrative, and Eli Lilly's robust pipeline, including orforglipron, is highlighted. Analysts frame the competition between Eli Lilly and Novo Nordisk as a "market-creation" dynamic, possibly leading to a structural duopoly in the obesity drug market. Eli Lilly's confidence in treating Alzheimer's further enhances its positive outlook. Investors may experience short-term fluctuations in both companies' stocks due to increased competition, but long-term prospects hinge on…